Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial
후보 중동 호흡기 증후군 코로나바이러스 바이러스 매개 백신의 안전성 및 면역원성: 용량 증량, 공개, 비무작위, 비통제, 1상 시험
Article
[키워드] absence
adverse event
AID
All participant
All participants
antibody
Antigen
Arabian Peninsula
assigned
baseline
cellular
cellular and humoral immunogenicity
cellular response
ChAdOx1
ChAdOx1 MERS
clinical
clinical development
clinical trial
coronavirus
Department
described
dose
dose-escalation
doses
effective
elicit
ELISA
enzyme
enzyme-linked immunospot
expressing
finding
FIVE
Follow-up
follow-up period
full-length
full-length spike surface glycoprotein
funding
healthy
hepatitis B
hepatitis B surface antigen
hepatitis C
hepatitis C antibodies
hepatitis C antibody
High-dose
high-dose group
HIV antibodies
humans
humoral
humoral immunogenicity
IgG
immunogenicity
ImmunoSpot
Infection
interferon
interferon-γ-linked enzyme-linked immunospot
intermediate-dose group
Intervention
Intramuscular injection
low-dose
Medicine
MERS
MERS-CoV
MERS-CoV spike antigen
Middle East
Middle East respiratory syndrome Coronavirus
Mild
mild in severity
moderate
neutralisation
neutralisation assay
Neutralising Antibodies
nine
Occurrence
Open-label
Oxford
participant
Phase 1
phase 1 trial
pre-vaccination test
pre-vaccination tests
pregnancy test
progression
proportion
Pseudotyped virus
public health
Registered
Relative risk
reported
resolved
respiratory
respiratory syndrome coronavirus
response
risk
Safe
Safety
Saudi Arabia
Serious Adverse Event
Serious Adverse Events
severe adverse event
significant increase
significantly higher
simian adenovirus-vectored vaccine
single dose
Support
surface antigen
Surface glycoprotein
T-cell
tested
Tolerability
trials
tropical medicine
urinary pregnancy test
vaccination
vectored vaccine
Viral
viral particle
Viral particles
virus neutralising assay
virus neutralising assays
was done
women
[DOI] 10.1016/S1473-3099(20)30160-2 PMC 바로가기 [Article Type] Article
[DOI] 10.1016/S1473-3099(20)30160-2 PMC 바로가기 [Article Type] Article